Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Events^a

By Christine B. Boers-Doets, RN, MSc
December 15, 2013

^aEditor’s Note: References to these tools are provided for educational purposes only. Terms of use for these tools may vary and some may be subject to copyright restrictions.

Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)

Patient Completed mcAEs Specific Symptom Experience Diary for Targeted Therapies

FACT-EGFRI-18

Skindex-16 and Hair Specific Skindex-29

HFS-14

mIAS Scale

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...

Apr

Today In Oncology

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer

Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa

Related Articles